PMID- 18198986
OWN - NLM
STAT- MEDLINE
DCOM- 20090609
LR  - 20221207
IS  - 0862-8408 (Print)
IS  - 0862-8408 (Linking)
VI  - 58
IP  - 1
DP  - 2009
TI  - Serum adipocyte fatty acid binding protein levels in patients with type 2 
      diabetes mellitus and obesity: the influence of fenofibrate treatment.
PG  - 93-99
AB  - Recent studies have demonstrated that adipocyte fatty acid binding proteins 
      (FABP) may play a role in the etiopathogenesis of insulin resistance. The aim of 
      our study was to assess serum FABP levels in obese patients with type 2 diabetes 
      mellitus (T2DM) before and after 3 months of treatment with PPAR-alpha agonist 
      fenofibrate (F) and to explore the relationship of FABP to biochemical parameters 
      and measures of insulin sensitivity assessed by hyperinsulinemic-isoglycemic 
      clamp. We measured biochemical parameters by standard laboratory methods, insulin 
      sensitivity by hyperinsulinemic-isoglycemic clamp and serum concentrations of 
      FABP by commercial ELISA kit in 11 obese females with T2DM before and after three 
      months of treatment with PPAR-alpha agonist fenofibrate and in 10 lean healthy 
      control women (C). Serum FABP levels were 2.5-fold higher in T2DM group relative 
      to C and were not affected by fenofibrate treatment (C: 20.6+/-2.1 microg/l, T2DM 
      before F: 55.6+/-5.7 microg/l, T2DM after F: 54.2+/-5.4 microg/l, p 0.0001 for C 
      vs. T2DM before F). Hyperinsulinemia during the clamp significantly suppressed 
      FABP levels in both C and T2DM group. FABP levels positively correlated with BMI, 
      triglyceride levels, blood glucose, glycated hemoglobin, atherogenic index and 
      insulin levels. An inverse relationship was found between FABP and HDL levels, 
      metabolic clearance rate of glucose, M/I and MCR(glc)/I sensitivity indexes. We 
      conclude that FABP levels are closely related to BMI, parameters of insulin 
      sensitivity, HDL levels and measures of diabetes compensation. This combination 
      makes FABP a valuable marker of metabolic disturbances in patients with type 2 
      diabetes mellitus.
FAU - Haluzik, M M
AU  - Haluzik MM
AD  - Third Department of Medicine, First Faculty of Medicine, Charles University, 
      Prague, Czech Republic. mhalu@1lf.cuni.cz
FAU - Anderlova, K
AU  - Anderlova K
FAU - Dolezalova, R
AU  - Dolezalova R
FAU - Adamikova, A
AU  - Adamikova A
FAU - Haluzikova, D
AU  - Haluzikova D
FAU - Housova, J
AU  - Housova J
FAU - Svacina, S
AU  - Svacina S
FAU - Haluzik, M
AU  - Haluzik M
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080117
PL  - Czech Republic
TA  - Physiol Res
JT  - Physiological research
JID - 9112413
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Fatty Acid-Binding Proteins)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Lipids)
RN  - 0 (PPAR alpha)
RN  - 0 (hemoglobin A1c protein, human)
RN  - U202363UOS (Fenofibrate)
SB  - IM
MH  - Biomarkers/blood
MH  - Blood Glucose/metabolism
MH  - Body Mass Index
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/blood/complications/*drug therapy
MH  - Fatty Acid-Binding Proteins/*blood
MH  - Female
MH  - Fenofibrate/*therapeutic use
MH  - Glucose Clamp Technique
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypolipidemic Agents/*therapeutic use
MH  - Insulin/blood
MH  - Insulin Resistance
MH  - Lipids/blood
MH  - Obesity/blood/complications/*drug therapy
MH  - PPAR alpha/agonists
MH  - Predictive Value of Tests
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2008/01/18 09:00
MHDA- 2009/06/10 09:00
CRDT- 2008/01/18 09:00
PHST- 2008/01/18 09:00 [pubmed]
PHST- 2009/06/10 09:00 [medline]
PHST- 2008/01/18 09:00 [entrez]
AID - 1371 [pii]
AID - 10.33549/physiolres.931371 [doi]
PST - ppublish
SO  - Physiol Res. 2009;58(1):93-99. doi: 10.33549/physiolres.931371. Epub 2008 Jan 17.